FDA’s “Limited-Use” Approval Pathway Moves Forward Without Congressional Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency seeks input on which diseases, beyond drug-resistant infections, could benefit from rapid approval of therapies for subpopulations of patients; public hearing in February will ask how labeling should best express the limited indications.